Cipher Pharmaceuticals Inc (TSE:CPH) has released an update.
Cipher Pharmaceuticals Inc. reported a modest year-over-year revenue growth of 2.4% to $21.2 million for 2023, alongside an increase in adjusted EBITDA by 2.2%. Their cash position stood at $39.8 million at the end of the year, with a notable 10% growth in Epuris revenue during the fourth quarter. The company also repurchased and cancelled over 1.5 million common shares under its issuer bid programs, reflecting its ongoing capital management strategies.
For further insights into TSE:CPH stock, check out TipRanks’ Stock Analysis page.
